MY ANALYSIS OF THIS PAST Q PLUS FORWARD PREDICTION:
(1) Freedom60 Sales (their main product) up 43%, led by an increasing recurring revenue stream as Hizentra and Vivaglobin patients tend to be patients for life who require REPR's tubing sets every month which run over $300 per year per patient for life. Hizentra sales continue to explode and the maker of Hizentra continues to promote REPR's Freedom60 device and tubing sets. 10Q forecasts further increases as a result of Hizentra drug approval last year and the Freedom60 now used for other drugs as well.
(2) I calculate that they sold around 1200/1300 Freedom60 devices in the Q bringing the total in operation to around 11,500 with a recurring revenue stream of now a rough guess of $880,000 per Q. The recurring revenue stream now going forward is very high and that alone should continue to make REPR profitable and growing with growing device sales being icing on the cake.
(3) Sequential results -- sales +16%, gross profit +18%, operating profit +59%, net income +66%. There will likely having a decline in SG&A expenses despite an increase in sales because I see no trade shows listed going forward plus a mechanical engineer and two sales associates were hired only temporarily.
(4) Rock solid balance sheet with a large and growing cash position, very little debt, and zero need for dilution.
FREEDOM60 sales of $1.15 million REQ-Q-VAC sales of $250,000 Total sales expectation = $1.4 million
Gross profit margin of 70% = $980,000 Other operating Expenses = $450,000 Operating Profit = $530,000 Income Taxes = $218,000 After-tax net income of $312,000 After-tax EPS of +.01 Current PE less than 5 for any price under .20 PE of 15 = .60/share target. With EPS of +.02/+.03 in future Qs in 2011, then target becomes $1.20/$1.80
Market Data 
Markets 
AI
